Diversity in Overall Activity Regulation of Ribonucleotide Reductase

Ribonucleotide reductase (RNR) catalyzes the reduction of ribonucleotides to the corresponding deoxyribonucleotides, which are used as building blocks for DNA replication and repair. This process is tightly regulated via two allosteric sites, the specificity site (s-site) and the overall activity site (a-site). The a-site resides in an N-terminal ATP cone domain that binds dATP or ATP and functions as an on/off switch, whereas the composite s-site binds ATP, dATP, dTTP, or dGTP and determines which substrate to reduce. There are three classes of RNRs, and class I RNRs consist of different combinations of α and β subunits. In eukaryotic and Escherichia coli class I RNRs, dATP inhibits enzyme activity through the formation of inactive α 6 and α 4 β 4 complexes, respectively. Here we show that the Pseudomonas aeruginosa class I RNR has a duplicated ATP cone domain and represents a third mechanism of overall activity regulation. Each α polypeptide binds three dATP molecules, and the N-terminal ATP cone is critical for binding two of the dATPs because a truncated protein lacking this cone could only bind dATP to its s-site. ATP activates the enzyme solely by preventing dATP from binding. The dATP-induced inactive form is an α 4 complex, which can interact with β 2 to form a non-productive α 4 β 2 complex. Other allosteric effectors induce a mixture of α 2 and α 4 forms, with the former being able to interact with β 2 to form active α 2 β 2 complexes. The unique features of the P. aeruginosa RNR are interesting both from evolutionary and drug discovery perspectives. Background: Ribonucleotide reductase (RNR) makes DNA building blocks. Results: Binding of three dATP molecules to the Pseudomonas aeruginosa class I RNR α subunit inactivates the enzyme by inducing an inert α 4 complex. Conclusion: The number of bound dATP molecules and the tetrameric complex are unique among RNRs. Significance: The novel inhibition mechanism of P. aeruginosa RNR is a potential drug target.